NCT03974022 · MORE INFO

Limitations, agreements, and source contact

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) · Source last updated 2026-01-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: Investigators, who are not employed by the sponsor, are free to publish study results. They must submit a copy of their publication to the sponsor for review at least 30 days in advance for manuscripts and 7 days for abstracts. The sponsor may request the removal of confidential information, identify patentable inventions, and provide comments. Publication may be delayed for up to 60 days to allow for a patent application. After this period, investigators can proceed with publication.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: clinicaltrials@dizalpharma.com
organization: Dizal Pharmaceuticals
phone: 862161097899
title: Li Zheng

Complete source fields

certain Agreement

other Details: Investigators, who are not employed by the sponsor, are free to publish study results. They must submit a copy of their publication to the sponsor for review at least 30 days in advance for manuscripts and 7 days for abstracts. The sponsor may request the removal of confidential information, identify patentable inventions, and provide comments. Publication may be delayed for up to 60 days to allow for a patent application. After this period, investigators can proceed with publication.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: clinicaltrials@dizalpharma.com
organization: Dizal Pharmaceuticals
phone: 862161097899
title: Li Zheng

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice